Keyphrases
Non-small Cell Lung Cancer (NSCLC)
80%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
58%
Overall Survival
41%
Lung Cancer
40%
Tumor
27%
Non-small Cell Lung Cancer Patients
26%
Immune Checkpoint Inhibitors
24%
Chemotherapy
23%
Durvalumab
21%
Lung Cancer Patients
18%
Confidence Interval
18%
Pembrolizumab
18%
Cancer Cells
16%
Small Cell Lung Cancer
15%
Progression-free Survival
14%
EGFR mutation
14%
Hazard Ratio
13%
Median Overall Survival
13%
Osimertinib
12%
Nivolumab
12%
Platinum-based Chemotherapy
12%
Programmed Death-ligand 1 (PD-L1)
12%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
11%
Tyrosine Kinase Inhibitor
11%
Cancer Patients
11%
Tumor Cells
10%
Adverse Events
10%
In Cancer
10%
Israel
10%
Chemoradiation
10%
Clinical Trials
10%
Retrospective Analysis
9%
Objective Response Rate
9%
Adenocarcinoma
9%
Epidermal Growth Factor Receptor
9%
Interferon-α (IFN-α)
9%
Metastatic Disease
8%
Immunohistochemistry
8%
Predictive Biomarker
8%
Early-stage Lung Cancer
8%
DNA Damage
8%
Cisplatin
7%
Median Progression-free Survival
7%
Multivariate Analysis
7%
Stromal Cells
7%
Monotherapy
7%
Erlotinib
7%
Melanoma Patients
6%
Brain Metastases
6%
Phase I Study
6%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Lung Cancer
50%
Overall Survival
39%
Neoplasm
39%
Epidermal Growth Factor Receptor
35%
Malignant Neoplasm
26%
Immune Checkpoint Inhibitor
21%
Progression Free Survival
21%
Chemoradiotherapy
20%
Immunotherapy
19%
Durvalumab
18%
Diseases
17%
Small Cell Lung Cancer
17%
Non-Small Cell Lung Cancer
17%
Tyrosine-Kinase Inhibitor
16%
Lung
14%
Adenocarcinoma
14%
Radiation Therapy
13%
Metastatic Carcinoma
13%
Nivolumab
12%
Clinical Trial
12%
Hazard Ratio
12%
Adverse Event
11%
Tumor Cell
11%
Cancer Cell
11%
Exon
11%
Biological Marker
11%
Pembrolizumab
10%
Osimertinib
9%
Breast Cancer
9%
Brain Metastasis
8%
Protein P53
7%
Cisplatin
7%
Immunohistochemistry
7%
Fibroblast
7%
Liquid Biopsy
6%
Programmed Death-Ligand 1
6%
Melanoma
6%
Biopsy Technique
6%
Long Term Survival
6%
Arm
6%
Erlotinib
6%
COVID-19
6%
Interferon
6%
Cell Invasion
6%
Colorectal Carcinoma
6%
Electrocorticography
6%
Albumin
5%
Angiogenesis
5%
Retrospective Study
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
83%
Lung Cancer
49%
Overall Survival
42%
Chemotherapy
39%
Neoplasm
34%
Malignant Neoplasm
32%
Epidermal Growth Factor Receptor
32%
Progression Free Survival
25%
Diseases
22%
Durvalumab
21%
Protein Tyrosine Kinase Inhibitor
18%
Chemoradiation Therapy
18%
Small Cell Lung Cancer
17%
Pembrolizumab
17%
Adverse Event
15%
Immunotherapy
15%
Protein P53
15%
Immune Checkpoint Inhibitor
15%
Osimertinib
12%
Biological Marker
10%
Cisplatin
10%
Nivolumab
9%
Clinical Trial
9%
Erlotinib
9%
Colorectal Carcinoma
9%
Adenocarcinoma
9%
Brain Metastasis
8%
Recurrent Disease
6%
Long Term Survival
6%
Cediranib
6%
Veliparib
6%
Coronavirinae
6%
Lactate Dehydrogenase
6%
Interferon
6%
Crizotinib
5%
microRNA
5%
Carboplatin
5%